SH U04722

SH U04722 is an investigational **small-molecule anticancer agent** developed by **Bayer** for **refractory solid tumors**. Publicly available information identifies it primarily through a Japanese **Phase I open-label dose-escalation study** that evaluated safety, tolerability, pharmacokinetics, and preliminary antitumor activity on a weekly administration schedule in patients with solid tumors. The specific molecular target and mechanism of action have not been clearly disclosed in the available public sources, so it is best described as an early-stage experimental oncology compound with **undisclosed mechanism**. Development appears to have stopped after Phase I, with the clinical trial record listed as terminated and no evidence of subsequent advancement.